Global intellectual property portfolio now stands at 67 issued patents
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of three new patents, one in the U.S. and two in Europe. ENDRA’s intellectual property portfolio now includes 67 issued patents worldwide, providing protection for the TAEUS® system with its novel hybrid ultrasound and thermoacoustic imaging technology.
The following three patents strengthening the TAEUS system’s proprietary position were issued:
U.S. Patent No. 11730374, titled “Radio Frequency Applicator for a Thermoacoustic Imaging System,” relates to a novel radio frequency applicator with an integrated wedge. The integrated wedge minimizes unwanted signals emanating from a patient’s skin, while maximizing radio frequency energy delivery to a patient’s targeted region of interest.
European Patent No. 3902495, titled “Method and System for Monitoring Tissue Temperature,” relates to a novel method and system for monitoring tissue temperature during surgical procedures by utilizing ENDRA’s TAEUS system. ENDRA expects its method and system to be effective for both thermotherapy and cryotherapy procedures. This patent is linked to its parent, U.S. Patent No. 10631734B1.
- European Patent No. 3806721, titled “Method and System for Determining Fractional Fat Content of Tissue,” covers a method and system for determining fractional fat content of tissue that takes into consideration the speed of sound in that tissue. This patent builds upon ENDRA's issued patents in the area of tissue fat quantification. Conventional ultrasound image formation methodologies assume a single speed of sound, while this issued patent leverages TAEUS' inherent sensitivity to fractional fat differences in tissue to estimate the actual speed of sound in tissue and thereby improves the accuracy of TAEUS fat quantification methodologies. The patent also describes a calibration methodology for fractional fat measurements, and is linked to its parent, U.S. Patent No. 10258277B2.
“These issued patents in two key geographies advance and protect ENDRA's thermoacoustic imaging systems in areas with high unmet clinical need," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "Currently, our portfolio includes 67 issued patents globally.”
About ENDRA Life Sciences Inc.
ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS® is designed to work in concert with the more than 700,000 ultrasound systems in use globally today. TAEUS® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.
All statements in this press release that are not based on historical fact are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of terms such as “approximate,” “anticipate,” “attempt,” “believe,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “hope,” “intend,” “may,” “plan,” “possible,” “potential,” “project,” “seek,” “should,” “will,” “would,” or other comparable terms (including the negative of any of the foregoing), although some forward-looking statements are expressed differently. Examples of forward-looking statements for ENDRA include, among others: estimates of the timing of future events and anticipated results of our development efforts, including the timing of submission for and receipt of required regulatory approvals and product launches; statements relating to future financial position and projected costs and revenue; expectations concerning ENDRA’s business strategy; and statements regarding ENDRA’s ability to find and maintain development partners. Forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements as a result of various factors including, among others: the ability to raise additional capital in order to continue as a going concern; the ability to obtain regulatory approvals necessary to sell ENDRA medical devices in certain markets in a timely manner, or at all; the ability to develop a commercially feasible technology and its dependence on third parties to design and manufacture its products; the impact of COVID-19 on ENDRA’s business plans; the ability to find and maintain development partners; market acceptance of ENDRA’s technology and the amount and nature of competition in its industry; ENDRA’s ability to protect its intellectual property; and the other risks and uncertainties described in the Risk Factors and Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of the Company’s most recent Annual Report on Form 10-K and in subsequent Quarterly Reports on Form 10-Q filed with the SEC. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this press release speak only as of the date of issuance, and ENDRA assumes no obligation to update any such forward-looking statements to reflect actual results or changes in expectations, except as otherwise required by law.